浙江医学2017，Vol.39Issue(19)：1653-1656,4.DOI:10.12056/j.issn.1006-2785.2017.39.19.2017-924
三阴性乳腺癌患者miR-155的表达及在新辅助化疗中的意义
Expression of miR-155 in triple-negative breast cancer and its significance in neoadjuvant chemotherapy
摘要
Abstract
Objective To investigate the expression of miR-155 in triple-negative breast cancer and its significance in neoadjuvant chemotherapy.Methods Twenty-three patients with triple-negative breast cancer,who received 4 cycles of neoadjuvant chemotherapy with epirubicin+cyclophosphamide regimen and successfully underwent radical mastectomy,were enrolled in the study.The tumor specimens and clinical data were collected before and after neoadjuvant chemotherapy.The expression of miR-155 in cancer tissue was detected by RT-PCR technique and the result was compared before and after neoadjuvant chemotherapy.The correlation of miR-155 expression with clinical and pathological features of patients was analyzed.Results The expression of miR-155 after neoadjuvant chemotherapy was significantly lower than that before neoadjuvant chemotherapy (P＜0.05).The expression of miR-155 in patients with Ki-67 overexpressing was significantly higher than that in those with Ki-67 low expression (P＜0.05).There was no significant difference in the expression of miR-155 among patients with different age,histological grade,clinical stage and lymph node metastasis status (all P ＞0.05).Conclusion The expression of miR-155 can be used as a molecular marker for the efficacy of neoadjuvant chemotherapy and the prognosis of patients with triple-negative breast cancer.Clinically,triple-negative breast cancer patients with miR-155 and Ki-67 over-expression may benefit from neoadjuvant chemotherapy.关键词
三阴性乳腺癌/miR-155/Ki-67/临床病理学特征Key words
Triple-negative breast cancer/miR-155/Ki-67/Clinico-pathological conference引用本文复制引用
谢小红,许雷来,顾锡冬..三阴性乳腺癌患者miR-155的表达及在新辅助化疗中的意义[J].浙江医学,2017,39(19):1653-1656,4.基金项目
浙江省医药卫生科技计划项目(2015KYB267) （2015KYB267）
